Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of HB0025 in Combination With Nab-Paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer.

NCT07376629 is registered in ClinicalTrials.gov with Huabo Biopharm Co., Ltd. as lead sponsor.

NCT NCT07376629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07376629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of HB0025 in Combination With Nab-Paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer.
Lead sponsor
Huabo Biopharm Co., Ltd.
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
August 14, 2025
Completion date
January 15, 2027
Enrollment
60 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc